Peri-menopause and the Face
Perimenopause and the Face — What Is Actually Happening, and Why It Matters for Aesthetic Medicine
The perimenopausal years bring some of the most significant and most rapid changes in facial ageing that a woman will experience. Understanding the biology behind those changes is the starting point for addressing them intelligently.
A turning point, not a continuation
Most women who come to us in their late forties describe a familiar experience. They have been noticing gradual changes for some time, a little more tiredness in the face, a little less firmness in the skin, but somewhere in this decade the pace has accelerated.
The changes they could previously attribute to the slow accumulation of years now feel different in character; more pronounced, more rapid, and less easily explained by lifestyle factors alone. They are right to notice the difference. Something has changed — and it has a name.
The perimenopausal transition, typically beginning in the mid to late forties and continuing through the cessation of menstruation, is associated with some of the most significant and most rapid changes in skin and facial structure that a woman will experience at any point in her life.
Understanding what is driving those changes, at a biological level, is the most useful thing a clinician can offer before any conversation about treatment begins.
The central role of oestrogen
Oestrogen is far more than a reproductive hormone. It has receptors throughout the body, including in skin cells, fibroblasts, and fat tissue, and it plays a central and multifaceted role in maintaining the structural integrity of the skin and face.
Three underlying mechanisms drive menopausal skin changes:
reduced systemic oestrogen levels due to diminished ovarian synthesis
lower local oestrogen production within the skin
decreased expression of oestrogen receptors in the skin.
The resulting hypoestrogenism leads to skin thinning, atrophy, reduced collagen, decreased elasticity, and reduced vascularity.
As oestrogen declines during perimenopause, the biological consequences are immediate and compound one another.
The skin's capacity to produce and maintain collagen is directly impaired
The extracellular matrix, which gives the dermis its structural organisation, begins to break down more rapidly.
Hyaluronic acid production falls, reducing the skin's ability to retain moisture.
The dermo-epidermal junction, which anchors the surface layers of the skin to the deeper dermal structure, begins to flatten and weaken.
These are not independent changes. They form a cascade, each reinforcing the others, and the cumulative effect is a face that can change significantly within a relatively short period of time.
The collagen collapse
The statistics on perimenopausal collagen loss are striking and deserve to be stated plainly.
In perimenopause, skin collagen levels decline rapidly, with a collagen reduction of approximately 30% in the first five years, followed by a further decline of 2% per year for the next fifteen years. An annual skin thickness reduction and constant collagen depletion of 1.1% and 2.1% respectively have been observed in menopausal women.
To contextualise these figures: we have already established in earlier pieces in this series that collagen production declines at approximately 1% per year from the mid-twenties onwards — a gradual process that accumulates over decades.
The perimenopausal transition accelerates this to a rate that is more than double, concentrated into a relatively short window. This collagen loss is more closely correlated with the duration of oestrogen deficiency than with chronological age. In other words, it is the hormonal change itself, not simply the passage of time, that drives the acceleration. Two women of the same age, one pre-menopausal and one post-menopausal, may have meaningfully different skin collagen content for this reason alone.
Volume loss and the facial fat compartments
The skin changes are only part of the picture. Oestrogen also plays a significant role in the distribution and maintenance of facial fat. As oestrogen declines, many women experience a shift in facial fat, with loss of volume in the cheeks, temples, and around the mouth, creating a more angular, less full facial appearance and accentuating bone structure in ways that may be perceived as ageing.
The facial fat compartments - discrete anatomical structures that provide volume and support to the overlying skin and soft tissue are hormonally sensitive. As oestrogen falls, these compartments lose volume and begin to descend, a process that compounds the surface changes in the skin by simultaneously withdrawing the structural support beneath it.
Volume loss of the facial fat compartments and the downward migration of the buccal fat pad leads to prominent nasolabial folds, marionette lines, and jowls, and gives the lower face a heavier appearance.
The face that a woman sees becoming heavier in the lower third while hollowing in the mid-face is not imagining things. She is observing two simultaneous processes, volume depletion above and tissue descent below, both driven in significant part by the same hormonal shift.
Dermal white adipose tissue — an emerging dimension
A more recently characterised aspect of menopausal skin change deserves mention, as it adds an important dimension to the clinical picture.
Dermal white adipose tissue (dWAT), found in the reticular dermis, is a crucial regenerative compartment involved in hair cycle regulation, antimicrobial peptide production, and extracellular matrix remodelling.
It acts as a hormonally responsive layer that supports skin health through paracrine signalling. Loss of dWAT disrupts skin homeostasis and is increasingly acknowledged as a contributing factor to menopausal skin changes.
This is a relatively new area of research and one with significant clinical implications; the loss of this dermal fat layer contributes to the thinning and fragility of the skin in ways that are distinct from collagen loss alone, and that may respond differently to treatment.
The question of HRT
No honest clinical discussion of perimenopause and the face can avoid the question of hormone replacement therapy.
HRT enhances skin quality by promoting collagen synthesis, elasticity, and hydration. Oestrogen replacement has been consistently shown to reverse these changes, leading to increased epidermal thickness and a significant increase in skin collagen content, correcting but not overcorrecting collagen deficiency. One study demonstrated a 6.49% increase in skin collagen after six months of oral oestrogen, and in another trial dermal thickness increased by 30%.
These are not trivial findings.
For patients who are appropriate candidates for HRT, the evidence suggests that addressing the hormonal deficit directly produces measurable skin benefits that no topical or injectable treatment can fully replicate, because they operate at the root cause rather than the downstream consequences.
We are not gynaecologists and we do not prescribe HRT. But we believe it is part of an honest clinical conversation to acknowledge its role and to encourage patients who have not had that conversation with their GP or a menopause specialist to do so.
The implications for aesthetic treatment
Understanding the perimenopausal biology of facial ageing changes the clinical assessment in several important ways.
First, it contextualises what the patient is seeing in the mirror. The acceleration she has noticed is real, it is biological, and it is driven by a specific and identifiable hormonal cascade, not by anything she has or has not done. That reassurance matters.
Second, it informs the treatment approach. A patient in perimenopause is not simply an older version of the patient she was at thirty-five. The character of the ageing is different; more rapid, more structural, and more likely to involve changes in skin quality that require a different treatment strategy than volume correction alone.
Biostimulatory treatments that work at the level of the fibroblast, Sculptra, Profhilo, polynucleotides, are particularly well suited to this stage of ageing, because they address the biological process that oestrogen decline has disrupted rather than simply correcting its visible surface consequences.
Third, it reinforces the importance of treating the face as a whole rather than responding to individual concerns in isolation.
The changes occurring during perimenopause are systemic in their origin and diffuse in their expression. A treatment plan that addresses only the most obvious concern, without considering the broader structural and skin quality picture, will produce incomplete and often unsatisfying results.
A conversation worth having earlier
One of the most consistent findings in the literature on perimenopausal skin changes is that women feel insufficiently informed about them.
In one survey, 50% of women felt that they had not been sufficiently informed about the dermatological symptoms of menopause, and 72% reported noticing changes in their skin during perimenopause and menopause.
That is a striking finding. The experience is nearly universal. The conversation, in clinical settings, is not.
We think that needs to change. A patient who understands what is happening to her face during perimenopause, why the changes feel different, why they have accelerated, what the biological mechanisms are, is better equipped to make informed decisions about her options. She is also less likely to feel that what she is experiencing is simply ageing badly, rather than responding to a specific and well-characterised hormonal event. There is an important psychological dimension to that distinction, and it matters as much as the clinical one.
The views expressed in Clinical Perspectives are the author's own and reflect their personal and professional experience in aesthetic medicine.
References
Viscomi B et al. Managing Menopausal Skin Changes: A Narrative Review of Skin Quality Changes, Their Aesthetic Impact, and the Actual Role of Hormone Replacement Therapy in Improvement. Journal of Cosmetic Dermatology. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12374573/
Dréno B et al. Dermatological Changes during Menopause and HRT: What to Expect? Cosmetics. 2024;11(1):9. https://www.mdpi.com/2079-9284/11/1/9
Thiboutot D et al. Round Table Discussion: Aesthetic Treatment Considerations for the Perimenopausal and Menopausal Patient. PMC. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12747467/
Managing Menopausal Skin: A Clinician's Review. European Medical Journal Dermatology. 2025;13(1):90–94. https://www.emjreviews.com/dermatology/article/managing-menopausal-skin-a-clinicians-review/
Menopause and Dermal White Adipose Tissue Depletion: Mechanistic Links, Adipogenesis, and Regenerative Therapeutic Replacement. PMC. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12793821/